Stem Cell Therapeutics to Provide Update on CD47 Program at the 2013 Annual Meeting of the American Society of Hematology

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, today announced it
will be providing an update on its immune checkpoint program targeting the CD47
protein at the 55th Annual Meeting of the American Society of Hematology, which
will be held December 7-10, 2013 in New Orleans, LA. Details of the poster
presentation, entitled "Blockade of CD47 Using SIRPaFc: Role of the Fc Region in
Anti-Leukemic Activity", are listed below: 




Date:       Monday December 9, 2013                                         
Time:       6:00 - 8:00 pm (CST)                                            
            615. Acute Myeloid Leukemia: Therapy, excluding Transplantation:
Session:    Poster III                                                      
Abstract #: 3935                                                            
Presenter:  Dr. Robert Uger, Chief Scientific Officer                       
Location:   Hall E, Ernest N. Morial Convention Center, New Orleans, LA     



About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-
cancer stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
[phone]
[e-mail]
www.stemcellthera.com


Investor Contact:
Jeff Ramson/Kirin Smith
ProActive Capital
[phone]
[e-mail]
[e-mail]